# OnCo record celestial-tncll (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/celestial-tncll/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "celestial-tncll", "NCT06073821" ;
  schema:name "CELESTIAL-TNCLL"@en ;
  schema:description "CELESTIAL-TNCLL tests the next-generation all-oral doublet against the current fixed-duration standard, with results expected from late 2026."@en ;
  schema:url <https://onco.cc/trials/celestial-tncll/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06073821>, <https://cllsociety.org/2026/07/an-update-on-sonrotoclax-plus-zanubrutinib-for-cll/> ;
  onco:status "active" ;
  onco:phase "3" ;
  schema:startDate "2023-11-11" ;
  onco:cancers <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/cll-treatment-naive/> ;
  onco:technologies <https://onco.cc/technologies/bcl2-inhibitors/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/bcl2/>, <https://onco.cc/targets/btk/> ;
  onco:drugs <https://onco.cc/drugs/sonrotoclax/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/obinutuzumab/> ;
  onco:companies <https://onco.cc/companies/beone/> .